ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Educational Symposium

Update on the Management of Recurrent Hyperkalemia Associated with RAAS Inhibitors in Patients with CKD and ESRD

November 04, 2022 | 12:45 PM - 01:45 PM

Location: Regency Ballroom T, Hyatt Regency Orlando

Session Description

RAAS inhibitors are the cornerstone therapy for several conditions in cardiorenal patients, such as hypertension, congestive heart failure, and CKD. Recurrent hyperkalemia frequently occurs in patients receiving RAAS inhibitors who have CKD resulting from hypertension or diabetes, with or without heart failure. As a result, RAAS inhibitor therapy is often down-titrated or discontinued, compromising its cardiorenal-protective benefit. Enabling patients to continue taking RAAS inhibitors by managing chronic hyperkalemia is a key goal of treatment.

This symposium provides updated information about recurrent hyperkalemia associated with RAAS inhibitors and its underlying pathophysiologic mechanisms.

Support is provided by an educational grant from CSL Vifor.

Learning Objective(s)

  • Describe the physiology of potassium metabolism
  • Explain the mechanisms underlying development of hyperkalemia in CKD
  • Discuss updates on recurrent hyperkalemia that occurs among patients with CKD while receiving RAAS inhibitors

Learning Pathway(s)

  • Fluid, Electrolyte, and Acid-Base Disorders
  • CKD Non-Dialysis


  • Alan C. Pao, MD